Name: Eli Lilly & Co. (NYSE:LLY) | Common-Size Liabilities and Stockholders’ Equity
Creator: Stock Analysis on Net

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Eli Lilly & Co., common-size consolidated balance sheet: liabilities and stockholders’ equity

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Short-term borrowings and current maturities of long-term debt	6.50%	10.79%	3.03%	3.15%	0.02%
Accounts payable	4.10%	4.06%	3.90%	3.42%	3.45%
Employee compensation	2.66%	2.58%	2.14%	1.96%	2.14%
Sales rebates and discounts	14.66%	18.26%	17.75%	14.03%	12.55%
Dividends payable	1.71%	1.83%	2.06%	1.81%	1.65%
Other current liabilities	6.42%	5.13%	5.75%	6.46%	6.96%
Current liabilities	36.05%	42.64%	34.63%	30.84%	26.77%
Long-term debt, excluding current maturities	36.24%	28.62%	29.78%	31.44%	35.57%
Accrued retirement benefits	1.65%	2.25%	2.64%	4.00%	8.78%
Long-term income taxes payable	5.16%	6.01%	7.50%	8.03%	8.23%
Other noncurrent liabilities	2.77%	3.50%	3.69%	6.92%	8.16%
Noncurrent liabilities	45.82%	40.39%	43.60%	50.40%	60.74%
Total liabilities	81.87%	83.03%	78.23%	81.24%	87.51%
Common stock, no par value	0.75%	0.93%	1.20%	1.22%	1.28%
Additional paid-in capital	9.45%	11.33%	13.99%	14.00%	14.54%
Retained earnings	17.21%	16.11%	20.29%	18.36%	16.79%
Employee benefit trust	-3.83%	-4.71%	-6.09%	-6.17%	-6.46%
Accumulated other comprehensive loss	-5.49%	-6.76%	-7.77%	-8.90%	-13.93%
Cost of common stock in treasury	-0.06%	-0.07%	-0.10%	-0.11%	-0.12%
Total Eli Lilly and Company shareholders’ equity	18.03%	16.83%	21.52%	18.40%	12.10%
Noncontrolling interests	0.10%	0.14%	0.25%	0.36%	0.39%
Total equity	18.13%	16.97%	21.77%	18.76%	12.49%
Total liabilities and equity	100.00%	100.00%	100.00%	100.00%	100.00%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Short-term borrowings and current maturities of long-term debt: This component exhibited a notable increase from 0.02% in 2020 to a peak of 10.79% in 2023, followed by a decrease to 6.5% in 2024. The sharp rise suggests a shift toward greater short-term financing or reclassification of debt maturities, which slightly reversed in the latest year.
Accounts payable: Accounts payable showed a gradual rising trend over the period, increasing from 3.45% in 2020 to 4.1% in 2024. This steady increase indicates a growing reliance on trade credit or higher purchasing activity on credit terms.
Employee compensation: This liability component remained relatively stable, fluctuating mildly around the 2% level, rising slightly to 2.66% in 2024. The data suggests a consistent but modest increase in employee-related obligations relative to total liabilities and equity.
Sales rebates and discounts: Sales rebates and discounts as a percentage of total liabilities and equity increased significantly from 12.55% in 2020 to a high of 18.26% in 2023, before coming down to 14.66% in 2024. The pronounced peak in 2023 may reflect intensified discounting or rebate programs to drive sales, easing somewhat in the final year.
Dividends payable: Dividends payable rose moderately from 1.65% in 2020 to 2.06% in 2022, then decreased slightly to 1.71% by 2024. This pattern implies a peak in dividend obligations mid-period followed by a slight reduction.
Other current liabilities: Other current liabilities declined steadily from 6.96% in 2020 to 5.13% in 2023, then increased again to 6.42% in 2024. This variability suggests shifting classifications or fluctuations in miscellaneous short-term obligations.
Current liabilities: The overall current liabilities proportion rose markedly from 26.77% in 2020 to a peak of 42.64% in 2023, before reducing to 36.05% in 2024. This substantial increase mainly reflects rising short-term borrowings and other current accruals, indicating a higher short-term funding reliance that somewhat eased later.
Long-term debt, excluding current maturities: Long-term debt decreased from 35.57% in 2020 to 28.62% in 2023, then rose sharply to 36.24% in 2024. The initial decline suggests debt repayments or refinancing, while the jump in 2024 may indicate new long-term borrowings or reclassification effects.
Accrued retirement benefits: Accrued retirement benefits showed a consistent declining trend from 8.78% in 2020 to 1.65% in 2024. This reduction points to either payment of retirement obligations, changes in actuarial assumptions, or benefit plan modifications reducing liabilities.
Long-term income taxes payable: Long-term income taxes payable decreased steadily from 8.23% in 2020 to 5.16% in 2024, reflecting either tax payments, adjustments, or changing deferred tax positions.
Other noncurrent liabilities: Other noncurrent liabilities declined significantly from 8.16% in 2020 to 2.77% in 2024, indicating a reduction in miscellaneous long-term obligations or reclassifications to current liabilities.
Noncurrent liabilities: Noncurrent liabilities decreased from 60.74% in 2020 to 40.39% in 2023, then rose to 45.82% in 2024. The trend reflects a broad decline in long-term obligations during the initial years, followed by some reversal, possibly linked to the increase in long-term debt in 2024.
Total liabilities: Total liabilities decreased from 87.51% in 2020 to 78.23% in 2022, then increased to 83.03% in 2023 and slightly declined to 81.87% in 2024. This suggests a general reduction in total liabilities during early years followed by a modest rebound thereafter.
Common stock, no par value: This equity component declined steadily from 1.28% in 2020 to 0.75% in 2024, indicating either share repurchases, capital structure adjustments, or declining relative book value of common stock.
Additional paid-in capital: Additional paid-in capital decreased from 14.54% in 2020 to 9.45% in 2024, showing a gradual decline that may stem from share buybacks, amortization of capital premiums, or adjustments in equity accounts.
Retained earnings: Retained earnings rose from 16.79% in 2020 to 20.29% in 2022, then declined to 16.11% in 2023 before a minor recovery to 17.21% in 2024. The fluctuation suggests variations in net earnings retention and possible dividend distributions.
Employee benefit trust: The negative balance in employee benefit trust decreased in absolute value, from -6.46% in 2020 to -3.83% in 2024, suggesting a strengthening of this equity component or reduced offsetting liabilities within this category.
Accumulated other comprehensive loss: Accumulated other comprehensive loss improved from -13.93% in 2020 to -5.49% in 2024, reflecting a reduction in unrealized losses or adverse valuation adjustments recognized in equity.
Cost of common stock in treasury: Cost of common stock in treasury as a percentage of total liabilities and equity decreased marginally from -0.12% in 2020 to -0.06% in 2024, indicating a slight reduction in treasury stock holdings or their offsetting impact.
Total Eli Lilly and Company shareholders’ equity: This aggregate equity measure increased from 12.1% in 2020 to 21.52% in 2022, then declined to 16.83% in 2023 with a slight recovery to 18.03% in 2024. Such variations reflect the combined effects of earnings, equity transactions, and other comprehensive income items influencing shareholders' equity.
Noncontrolling interests: Noncontrolling interests decreased from 0.39% in 2020 to 0.10% in 2024, indicating a reduction in the minority interest within consolidated subsidiaries.
Total equity: Total equity mirrored trends in primary equity components, rising from 12.49% in 2020 to 21.77% in 2022, then decreasing to 16.97% in 2023 and increasing slightly to 18.13% in 2024, illustrating fluctuations in net assets attributable to shareholders over time.
Total liabilities and equity: Consistently balanced at 100%, this confirms the proper composition of the capital structure throughout the years under review.

Download chart